Lack of evidence for reduced plasma apo B48 catabolism in patients with heterozygous familial hypercholesterolemia carrying the same null LDL receptor gene mutation

Atherosclerosis

Volumn 172, Issue 2, 2004, Pages 367-373

  Tremblay, André J ^a   Lamarche, Benoît ^a,b   Ruel, Isabelle ^a,b   Hogue, Jean Charles ^a   Bergeron, Jean ^a   Gagné, Claude ^a   Couture, Patrick ^a  

^a Laval University   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Apolipoprotein B48; Chylomicron remnants; Familial hypercholesterolemia; LDL receptor; LDL receptor related protein

Indexed keywords

APOLIPOPROTEIN B48; APOLIPOPROTEIN E3; CHYLOMICRON; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; ARTICLE; BODY MASS; CATABOLITE REPRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE DELETION; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; MALE; NULL ALLELE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RECEPTOR GENE;

EID: 0842281358     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2003.11.011     Document Type: Article

References (46)

1. Zilversmit D.B. Atherogenesis: a postprandial phenomenon. Circulation. 60:1979;473-485.
2. Simons L.A., Dwyer T., Simons J., Bernstein L., Mock P., Poonia N.S.et al. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis. 65:1987;181-189.
3. Patsch J.R., Miesenbock G., Hopferwieser T., Muhlberger V., Knapp E., Dunn J.K.et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler. Thromb. 12:1992;1336-1345.
4. Phillips M.L., Pullinger C., Kroes I., Kroes J., Hardman D.A., Chen G.et al. A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. J. Lipid Res. 38:1997;1170-1177.
5. Mahley R.W., Ji Z.S. Remnant lipoprotein metabolism. Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40:1999;1-16.
6. Martins I.J., Hone E., Chi C., Seydel U., Martins R.N., Redgrave T.G. Relative roles of LDLr and LRP in the metabolism of chylomicron remnants in genetically manipulated mice. J. Lipid Res. 41:2000;205-213.
7. Yu K.C., Chen W., Cooper A.D. LDL receptor-related protein mediates cell-surface clustering and hepatic sequestration of chylomicron remnants in LDLR-deficient mice. J. Clin. Invest. 107:2001;1387-1394.
8. Langer T., Strober W., Levy R.I. The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia. J. Clin. Invest. 51:1972;1528-1536.
9. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
10. Bowler A., Redgrave T.G., Mamo J.C. Chylomicron-remnant clearance in homozygote and heterozygote Watanabe-heritable-hyperlipidaemic rabbits is defective. Lack of evidence for an independent chylomicron-remnant receptor. Biochem. J. 276:1991;381-386.
11. Choi S.Y., Fong L.G., Kirven M.J., Cooper A.D. Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo. J. Clin. Invest. 88:1991;1173-1181.
12. Ishibashi S., Perrey S., Chen Z., Osuga J., Shimada M., Ohashi K.et al. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J. Biol. Chem. 271:1996;22422-22427.
13. Rubinsztein D.C., Cohen J.C., Berger G.M., van der Westhuyzen D.R., Coetzee G.A., Gevers W. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J. Clin. Invest. 86:1990;1306-1312.
14. Watts G.F., Barrett P.H., Marais A.D., Dane-Stewart C.A., Martins I.J., Dimmitt S.B. Chylomicron remnant metabolism in familial hypercholesterolaemia studied with a stable isotope breath test. Atherosclerosis. 157:2001;519-523.
15. Cabezas M.C., de Bruin T.W., Westerveld H.E., Meijer E., Erkelens D.W. Delayed chylomicron remnant clearance in subjects with heterozygous familial hypercholesterolaemia. J. Intern. Med. 244:1998;299-307.
16. Mamo J.C., Smith D., Yu K.C., Kawaguchi A., Harada-Shiba M., Yamamura T.et al. Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolaemia. Eur. J. Clin. Invest. 28:1998;379-384.
17. Twickler T.B., Dallinga-Thie G.M., de Valk H.W., Schreuder P.C., Jansen H., Cabezas M.C.et al. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20:2000;2422-2427.
18. Hobbs H.H., Brown M.S., Russell D.W., Davignon J., Goldstein J.L. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N. Engl. J. Med. 317:1987;734-737.
19. Harris J, Benedict F. A biometric study of basal metabolism in man. Carnegie Institution, Washington, DC, 1919.
20. Moorjani S., Dupont A., Labrie F., Lupien P.J., Brun D., Gagné C.et al. Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism. 36:1987;244-250.
21. Havel R.J., Eder H., Bragdon J. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1955;1345-1353.
22. + precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin. Chem. 24:1978;853-856.
23. Kotite L., Bergeron N., Havel R.J. Quantification of apolipoproteins B-100, B-48, and E in human triglyceride-rich lipoproteins. J. Lipid Res. 36:1995;890-900.
24. Zilversmit D.B., Shea T.M. Quantitation of apoB-48 and apoB-100 by gel scanning or radio-iodination. J. Lipid Res. 30:1989;1639-1646.
25. Welty F.K., Lichtenstein A.H., Barrett P.H., Dolnikowski G.G., Schaefer E.J. Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler. Thromb. Vasc. Biol. 19:1999;2966-2974.
26. Cobelli C., Toffolo G., Bier D.M., Nosadini R. Models to interpret kinetic data in stable isotope tracer studies. Am. J. Physiol. 253:1987;E551-E564.
27. Cohn J., Wagner D., Cohn S., Millar J., Schaefer E. Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I. production in human subjects using deuterated leucine. Effect of fasting and feeding. J. Clin. Invest. 85:1990;804-811.
28. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31:1990;545-548.
29. Couture P., Morissette J., Gaudet D., Vohl M.C., Gagné C., Bergeron J.et al. Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. Atherosclerosis. 143:1999;145-151.
30. Moorjani S., Roy M., Torres A., Bétard C., Gagné C., Lambert M.et al. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet. 341:1993;1303-1306.
31. Gaudet D., Vohl M.C., Couture P., Moorjani S., Tremblay G., Perron P.et al. Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men. Atherosclerosis. 143:1999;153-161.
32. Welty F.K., Lichtenstein A.H., Barrett P.H., Jenner J.L., Dolnikowski G.G., Schaefer E.J. Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans. Arterioscler. Thromb. Vasc. Biol. 20:2000;1807-1810.
33. Eriksson M., Angelin B., Henriksson P., Ericsson S., Vitols S., Berglund L. Metabolism of lipoprotein remnants in humans. Studies during intestinal infusion of fat and cholesterol in subjects with varying expression of the low density lipoprotein receptor. Arterioscler. Thromb. 11:1991;827-837.
34. Gudnason V., Day I.N.M., Humphries S.E. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene in patients with familial hypercholesterolemia. Arterioscler. Thromb. 14:1994;1717-1722.
35. Gaudet D., Vohl M.C., Perron P., Tremblay G., Gagné C., Lesiege D.et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation. 97:1998;871-877.
36. Karpe F., Bell M., Bjorkegren J., Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler. Thromb. Vasc. Biol. 15:1995;199-207.
37. Krasinski S., Cohn J., Russell R., Schaefer E. Postprandial plasma vitamin A metabolism in humans: a reassessment of the use of plasma retinyl esters as markers for intestinally derived chylomicrons and their remnants. Metabolism. 39:1990;357-365.
38. Boerwinkle E., Brown S., Sharrett A.R., Heiss G., Patsch W. Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. Am. J. Hum. Genet. 54:1994;341-360.
39. Lemieux S., Fontani R., Uffelman K.D., Lewis G.F., Steiner G. Apolipoprotein B-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins. J. Lipid Res. 39:1998;1964-1971.
40. Willnow T.E., Sheng Z., Ishibashi S., Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 264:1994;1471-1474.
41. Willnow T.E., Armstrong S.A., Hammer R.E., Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc. Natl. Acad. Sci. U.S.A. 92:1995;4537-4541.
42. Rohlmann A., Gotthardt M., Hammer R.E., Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:1998;689-695.
43. Twisk J., Gillian-Daniel D.L., Tebon A., Wang L., Barrett P.H., Attie A.D. The role of the LDL receptor in apolipoprotein B secretion. J. Clin. Invest. 105:2000;521-532.
44. Dane-Stewart C.A., Watts G.F., Mamo J.C., Dimmitt S.B., Barrett P.H., Redgrave T.G. Elevated apolipoprotein B-48 and remnant-like particle- cholesterol in heterozygous familial hypercholesterolaemia. Eur. J. Clin. Invest. 31:2001;113-117.
45. de Sauvage Nolting P.R., Twickler M.B., Dallinga-Thie G.M., Buirma R.J., Hutten B.A., Kastelein J.J. Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy. Circulation. 106:2002;788-792.
46. Liao W., Hui T.Y., Young S.G., Davis R.A. Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER. J. Lipid Res. 44:2003;978-985.